Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV
Purpose of Review
Increasing hepatitis C virus (HCV) cases over the past decade have raised concerns about subsequent increased cases in infants due to mother to child transmission (MTCT). Many are reminded of the early days of HIV and the rationale for using antiretroviral agents during pregnancy.
Direct-acting antivirals (DAAs) that are highly potent, all-oral, short-duration regimens that cure HCV have led many to consider what it would entail to use DAAs for pregnant women. Considering HIV and Hepatitis B virus (HBV) as two infections with MTCT to draw lessons from, DAA use to interrupt HCV MTCT comes with risks, costs, and many potential benefits.
When considering how to effectively curb the current epidemic of HCV in the US population, using DAAs to treat pregnant women with HCV offers potential benefits to the mother immediately, to the pair in the short-term and to the child, family, and society over a lifetime.
KeywordsHepatitis C Pregnancy Mother to children transmission Vertical transmission
Mother to children transmission
Directly acting antivirals
Sustained virologic response
Compliance with Ethical Standards
Conflict of Interest
A. Sidney Barritt IV declares no conflict of interest. Ravi Jhaveri received a grant from Merck and has participated in clinical trials with Gilead and Abbvie.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 4.Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9. https://doi.org/10.1016/S0140-6736(15)60159-3.CrossRefPubMedGoogle Scholar
- 5.Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97. https://doi.org/10.1016/S0140-6736(14)61793-1.CrossRefPubMedGoogle Scholar
- 7.Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062–8. https://doi.org/10.1016/S1473-3099(17)30496-6.CrossRefPubMedGoogle Scholar
- 14.Jhaveri R, Hashem M, El-Kamary SS, Saleh DA, Sharaf S, El-Mougy F, et al. Hepatitis C virus (HCV) vertical transmission in 12-month-old infants born to HCV-infected women and assessment of maternal risk factors. Open Forum Infect Dis. 2015;2(2):ofv089. https://doi.org/10.1093/ofid/ofv089.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41(1):45–51.Google Scholar
- 23.European Paediatric Hepatitis C Virus Network. A significant sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005;192(11):1872–9. https://doi.org/10.1086/497695.
- 27.Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-Medina A, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011;53(6):1830–8. https://doi.org/10.1002/hep.24298.CrossRefPubMedGoogle Scholar
- 29.Hashem M, Jhaveri R, Saleh DA, Sharaf S, El-Mougy F, Abdelsalam L, et al. Spontaneous viral load decline and subsequent clearance of chronic hepatitis C virus in postpartum women correlates with favorable interleukin-28B gene allele. Clin Infect Dis. 2017;65(6):999–1005. https://doi.org/10.1093/cid/cix445.CrossRefPubMedGoogle Scholar
- 30.Dickover RE, Dillon M, Leung KM, Krogstad P, Plaeger S, Kwok S, et al. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis. 1998;178(2):375–87.CrossRefPubMedGoogle Scholar
- 31.Frederick T, Mascola L, Eller A, O'Neil L, Byers B. Progression of human immunodeficiency virus disease among infants and children infected perinatally with human immunodeficiency virus or through neonatal blood transfusion. Los Angeles County Pediatric AIDS Consortium and the Los Angeles County-University of Southern California Medical Center and the University of Southern California School of Medicine. Pediatr Infect Dis J. 1994;13(12):1091–7.CrossRefPubMedGoogle Scholar
- 32.Diaz C, Hanson C, Cooper ER, Read JS, Watson J, Mendez HA, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the women and infants transmission study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(3):221–8.CrossRefPubMedGoogle Scholar
- 33.Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group protocol 076 study group. N Engl J Med. 1994;331(18):1173–80. https://doi.org/10.1056/NEJM199411033311801.CrossRefPubMedGoogle Scholar
- 34.Achievements in public health. Reduction in perinatal transmission of HIV infection—United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592–7.Google Scholar
- 37.Schillie S, Walker T, Veselsky S, Crowley S, Dusek C, Lazaroff J, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135(5):e1141–7. https://doi.org/10.1542/peds.2014-3213
- 38.Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103. https://doi.org/10.1111/j.1365-2893.2008.01056.x.CrossRefPubMedGoogle Scholar
- 39.Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19(48):9377–82. https://doi.org/10.3748/wjg.v19.i48.9377.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23. https://doi.org/10.1016/S0140-6736(13)62121-2.CrossRefPubMedGoogle Scholar
- 47.Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8. https://doi.org/10.7326/0003-4819-156-4-201202210-00004.CrossRefPubMedGoogle Scholar
- 52.Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21, 21 e1–6. https://doi.org/10.1053/j.gastro.2009.09.067.CrossRefPubMedGoogle Scholar
- 55.Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2016;176(1):65–73. https://doi.org/10.1001/jamainternmed.2015.6011.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531–46. https://doi.org/10.18553/jmcp.2011.17.7.531.PubMedGoogle Scholar